The current study was interested in compounds that are not currently approved to treat cancer and based on preliminary literature searches the following ‘hits’ were selected for validation and characterisation: (i) the TBX2 ‘hits’, vardenafil hydrochloride and niclosamide (Figure 3A,B); (ii) the TBX3 ‘hits’, piroctone olamine and pyrvinium pamoate (Figure 3C,D); and (iii) the TBX2 and TBX3 ‘hit’, tacrolimus (Figure 3E). The gene discussed is TBX2; the disease is cancer.